Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer

Hisato Igarashi, Tetsuhide Ito, Ken Kawabe, Terumasa Hisano, Yoshiyuki Arita, Toyoma Kaku, Ryoichi Takayanagi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim: To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly. Methods: We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m2. After that, maintenance systemic chemotherapy with gemcitabine, at a dose of 1000 mg/m2, was administered weekly for 3 wk with 1-wk rest until disease progression or unacceptable toxicity developed. Results: Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy; one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis during an early stage of the therapy. The median survival was 15.0 mo and the overall 1-year survival rate was 60%, while the median progression-free survival was 8.0 mo. The subgroup which showed the reduction of tumor development, more than 50% showed a tendency for a better prognosis; however, other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 mo and 27.7 mo, respectively. Conclusion: Chemoradiotherapy with low-dose gemcitabine administered twice weekly could be effective to patients with locally advanced pancreatic cancer; however, patients developing liver metastases had a worse prognosis. Another chemoradiotherapy strategy might be needed for those patients, such as administrating one or two cycles of chemotherapy initially, followed by chemoradiotherapy for the cases with no distant metastases.

Original languageEnglish
Pages (from-to)5311-5315
Number of pages5
JournalWorld Journal of Gastroenterology
Volume14
Issue number34
DOIs
Publication statusPublished - Sep 14 2008

Fingerprint

gemcitabine
Chemoradiotherapy
Pancreatic Neoplasms
Neoplasm Metastasis
Survival
Liver
Maintenance Chemotherapy
Radiation-Sensitizing Agents
Interstitial Lung Diseases
Secondary Prevention
Disease-Free Survival
Disease Progression
Radiotherapy
Survival Rate

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. / Igarashi, Hisato; Ito, Tetsuhide; Kawabe, Ken; Hisano, Terumasa; Arita, Yoshiyuki; Kaku, Toyoma; Takayanagi, Ryoichi.

In: World Journal of Gastroenterology, Vol. 14, No. 34, 14.09.2008, p. 5311-5315.

Research output: Contribution to journalArticle

Igarashi, H, Ito, T, Kawabe, K, Hisano, T, Arita, Y, Kaku, T & Takayanagi, R 2008, 'Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer', World Journal of Gastroenterology, vol. 14, no. 34, pp. 5311-5315. https://doi.org/10.3748/wjg.14.5311
Igarashi, Hisato ; Ito, Tetsuhide ; Kawabe, Ken ; Hisano, Terumasa ; Arita, Yoshiyuki ; Kaku, Toyoma ; Takayanagi, Ryoichi. / Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. In: World Journal of Gastroenterology. 2008 ; Vol. 14, No. 34. pp. 5311-5315.
@article{82bc263b010644d9bd0fdcbcb9d3a396,
title = "Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer",
abstract = "Aim: To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly. Methods: We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m2. After that, maintenance systemic chemotherapy with gemcitabine, at a dose of 1000 mg/m2, was administered weekly for 3 wk with 1-wk rest until disease progression or unacceptable toxicity developed. Results: Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy; one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis during an early stage of the therapy. The median survival was 15.0 mo and the overall 1-year survival rate was 60{\%}, while the median progression-free survival was 8.0 mo. The subgroup which showed the reduction of tumor development, more than 50{\%} showed a tendency for a better prognosis; however, other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 mo and 27.7 mo, respectively. Conclusion: Chemoradiotherapy with low-dose gemcitabine administered twice weekly could be effective to patients with locally advanced pancreatic cancer; however, patients developing liver metastases had a worse prognosis. Another chemoradiotherapy strategy might be needed for those patients, such as administrating one or two cycles of chemotherapy initially, followed by chemoradiotherapy for the cases with no distant metastases.",
author = "Hisato Igarashi and Tetsuhide Ito and Ken Kawabe and Terumasa Hisano and Yoshiyuki Arita and Toyoma Kaku and Ryoichi Takayanagi",
year = "2008",
month = "9",
day = "14",
doi = "10.3748/wjg.14.5311",
language = "English",
volume = "14",
pages = "5311--5315",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "34",

}

TY - JOUR

T1 - Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer

AU - Igarashi, Hisato

AU - Ito, Tetsuhide

AU - Kawabe, Ken

AU - Hisano, Terumasa

AU - Arita, Yoshiyuki

AU - Kaku, Toyoma

AU - Takayanagi, Ryoichi

PY - 2008/9/14

Y1 - 2008/9/14

N2 - Aim: To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly. Methods: We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m2. After that, maintenance systemic chemotherapy with gemcitabine, at a dose of 1000 mg/m2, was administered weekly for 3 wk with 1-wk rest until disease progression or unacceptable toxicity developed. Results: Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy; one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis during an early stage of the therapy. The median survival was 15.0 mo and the overall 1-year survival rate was 60%, while the median progression-free survival was 8.0 mo. The subgroup which showed the reduction of tumor development, more than 50% showed a tendency for a better prognosis; however, other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 mo and 27.7 mo, respectively. Conclusion: Chemoradiotherapy with low-dose gemcitabine administered twice weekly could be effective to patients with locally advanced pancreatic cancer; however, patients developing liver metastases had a worse prognosis. Another chemoradiotherapy strategy might be needed for those patients, such as administrating one or two cycles of chemotherapy initially, followed by chemoradiotherapy for the cases with no distant metastases.

AB - Aim: To evaluate the chemoradiotherapy for locally advanced pancreatic cancer utilizing low dose gemcitabine as a radiation sensitizer administered twice weekly. Methods: We performed a retrospective analysis of chemoradiotherapy utilizing gemcitabine administered twice weekly at a dose of 40 mg/m2. After that, maintenance systemic chemotherapy with gemcitabine, at a dose of 1000 mg/m2, was administered weekly for 3 wk with 1-wk rest until disease progression or unacceptable toxicity developed. Results: Eighteen patients with locally advanced unresectable pancreatic cancer were enrolled. Three of those patients could not continue with the therapy; one patient had interstitial pneumonia during radiation therapy and two other patients showed liver metastasis or peritoneal metastasis during an early stage of the therapy. The median survival was 15.0 mo and the overall 1-year survival rate was 60%, while the median progression-free survival was 8.0 mo. The subgroup which showed the reduction of tumor development, more than 50% showed a tendency for a better prognosis; however, other parameters including age, gender and performance status did not correlate with survival. The median survival of the groups that died of liver metastasis and peritoneal metastasis were 13.0 mo and 27.7 mo, respectively. Conclusion: Chemoradiotherapy with low-dose gemcitabine administered twice weekly could be effective to patients with locally advanced pancreatic cancer; however, patients developing liver metastases had a worse prognosis. Another chemoradiotherapy strategy might be needed for those patients, such as administrating one or two cycles of chemotherapy initially, followed by chemoradiotherapy for the cases with no distant metastases.

UR - http://www.scopus.com/inward/record.url?scp=64849113694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849113694&partnerID=8YFLogxK

U2 - 10.3748/wjg.14.5311

DO - 10.3748/wjg.14.5311

M3 - Article

C2 - 18785284

AN - SCOPUS:64849113694

VL - 14

SP - 5311

EP - 5315

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 34

ER -